Nucleate announces first impact report: 5 Years of Nucleate! 🎉 Read more about the 2019-2023 Impact Report here:

Join us at the 2025 Nucleate Summit as industry experts dive deep into the tradeoffs between going public and being acquired. Discover what each path means for your science, team, and long-term vision. 🎟️ Register now for the 2025 Nucleate Summit:

🧬 Cristina Montero - Investment Research leader at RA Capital.🧬 Nolan Townsend - CEO of Lexeo Therapeutics and former President at Pfizer Rare Disease.🧬 Jo Viney - Founder, President, and CEO of Seismic Therapeutics.

Meet the Speakers:.⏱️ Warren Browne - CEO & Founder of Browne Consulting.🧬 Sam Hall - Co-founder & Managing Partner of Scion Life Sciences.🧬 Jolyon Martin - Partner at Vie Ventures and co-founder of ArkVax.

🌊 Tide Talk: Exits in Biotech – IPO vs Pharma Acquisition . Building with endgame in mind is crucial for any biotech company! Whether you're aiming for an IPO, considering pharma acquisition, or somewhere in between, your exit strategy shapes how you fund, scale, and operate.

We are grateful for their support and can’t wait to see their coverage of the Summit, contributing to the ongoing dialogue about the future of biotech!. 🌐 Learn more about Science in Boston:

By amplifying the voices of emerging scientists and innovators, Science in Boston helps highlight local events, funding opportunities, and scientific achievements, fueling collaboration and advancing science in the region.

Science in Boston is an official media sponsor for the 2025 Nucleate Summit! 🎉 As the go-to source for life science news and events in the Greater Boston area, Science in Boston plays a key role in keeping the scientific community connected and informed.

🔗 Stay up to date and learn more about the event on our website here:

This Tide Talk is a must-attend session for anyone in biotech, as AI continues to disrupt the industry. Gain invaluable insights on the future of AI-powered biotech innovation and how to prepare for rapid changes in the field.

The Panelists:.🔹Tony Kulesa – Partner at Pillar VC.🔹Beth Porter – Serial entrepreneur and mentor at C10 Labs.🔹AJ Venkatakrishnan – AI expert leading partnerships at nference.🔹Michael Retchin – Co-founder & CEO of Scale Medicine.🔹Dan Spellman – Leads Oracle’s AI + OCI group.

🌊 2025 Alumni Summit Tide Talk: Beyond LLMs – How Automation and AI are Reshaping Biotech . AI is evolving beyond large language models (LLMs) and making a huge impact on biotech!

Want to see how Balto AI Assistant can streamline your drug discovery? Try it for FREE today: 🌐 Learn more about Deep Origin:

🚀 Welcoming Deep Origin as a Summit Silver Sponsor!. We are thrilled to have Deep Origin as a Silver Sponsor for the 2025 Nucleate Summit! Deep Origin is revolutionizing drug discovery by leveraging AI grounded in physics to de-risk the process and accelerate research.

🎟️ Register now to join us at the 2025 Nucleate Summit:

Bob’s belief in the power of policy to drive scientific progress will take center stage in this keynote, where he’ll share insights on how public policy shapes the future of biotech innovation and how strategic advocacy can transform scientific landscapes.

🌟 Main Stage Keynote: Public Policy & The Birth of the Kendall Square Ecosystem 🌟. Join us at the 2025 Nucleate Summit to hear from Bob Coughlin, a pivotal figure in the biotech sector and former CEO of MassBio.

Biotech may be global, but the best ecosystems invest in themselves. Our new report for the Hidden Layers series on Nucleate's Signal platform reveals which cities retain local capital and which rely on outside dollars. 🔗 Read:

🎟️ Get your tickets now to join us at the 2025 Nucleate Summit: Buy tickets here:

This affordable service is perfect for researchers analyzing microbiomes, from environmental studies to clinical research. Learn more about this service here:

Exciting news: Plasmidsaurus now offers microbiome sequencing from crude samples for just $45 per sample with next-day turnaround!.